HomeCompareAPTO vs VYM

APTO vs VYM: Dividend Comparison 2026

APTO yields 116.96% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTO wins by $7.59M in total portfolio value
10 years
APTO
APTO
● Live price
116.96%
Share price
$1.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.61M
Annual income
$2,839,061.37
Full APTO calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — APTO vs VYM

📍 APTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTOVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTO + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APTO pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTO
Annual income on $10K today (after 15% tax)
$9,941.52/yr
After 10yr DRIP, annual income (after tax)
$2,413,202.16/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, APTO beats the other by $2,412,965.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTO + VYM for your $10,000?

APTO: 50%VYM: 50%
100% VYM50/50100% APTO
Portfolio after 10yr
$3.82M
Annual income
$1,419,669.96/yr
Blended yield
37.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on APTO right now

APTO
Analyst Ratings
10
Buy
1
Hold
Consensus: Buy
Altman Z
-114.1
Piotroski
3/9
VYM
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTO buys
0
VYM buys
0
No recent congressional trades found for APTO or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTOVYM
Forward yield116.96%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7.61M$27.8K
Annual income after 10y$2,839,061.37$278.55
Total dividends collected$6.91M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: APTO vs VYM ($10,000, DRIP)

YearAPTO PortfolioAPTO Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$22,396$11,695.91$11,151$241.44+$11.2KAPTO
2$48,444$24,480.41$12,413$246.79+$36.0KAPTO
3$101,324$49,488.77$13,794$251.79+$87.5KAPTO
4$205,154$96,737.39$15,306$256.47+$189.8KAPTO
5$402,568$183,053.76$16,960$260.84+$385.6KAPTO
6$766,451$335,702.65$18,768$264.92+$747.7KAPTO
7$1,417,434$597,331.71$20,745$268.71+$1.40MAPTO
8$2,549,060$1,032,405.58$22,905$272.24+$2.53MAPTO
9$4,462,671$1,735,176.87$25,265$275.51+$4.44MAPTO
10$7,614,120$2,839,061.37$27,842$278.55+$7.59MAPTO

APTO vs VYM: Complete Analysis 2026

APTOStock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Full APTO Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this APTO vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTO vs SCHDAPTO vs JEPIAPTO vs OAPTO vs KOAPTO vs MAINAPTO vs VIGAPTO vs DGROAPTO vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.